YL-109 5 mg | 98.00%
TargetMol
YL-109, a novel anticancer agent, can inhibit breast Y cell growth and invasiveness in vitro and in vivo.
More Information Supplier PageYL-109
Search Results
YL-109 10 mg | 98.00%
TargetMol
YL-109, a novel anticancer agent, can inhibit breast Y cell growth and invasiveness in vitro and in vivo.
More Information Supplier PageYL-109
BRD4770 5 mg | 99.82%
TargetMol
BRD4770 is a histone methyltransferase G9a inhibitor and induces cell senescence.
More Information Supplier PageBRD4770
BRD4770 50 mg | 99.82%
TargetMol
BRD4770 is a histone methyltransferase G9a inhibitor and induces cell senescence.
More Information Supplier PageBRD4770
BRD4770 25 mg | 99.82%
TargetMol
BRD4770 is a histone methyltransferase G9a inhibitor and induces cell senescence.
More Information Supplier PageBRD4770
BRD4770 10 mg | 99.82%
TargetMol
BRD4770 is a histone methyltransferase G9a inhibitor and induces cell senescence.
More Information Supplier PageBRD4770
BRD4770 100 mg | 99.82%
TargetMol
BRD4770 is a histone methyltransferase G9a inhibitor and induces cell senescence.
More Information Supplier PageBRD4770
Atglistatin 10 mg | 99.81%
TargetMol
Atglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.
More Information Supplier PageAtglistatin
Atglistatin 100 mg | 99.81%
TargetMol
Atglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.
More Information Supplier PageAtglistatin
Omipalisib 5 mg | 99.16%
TargetMol
GSK2126458 is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity.
More Information Supplier PageOmipalisib
